These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12905610)

  • 1. [Treatment of premenopausal patients with advanced or recurrent breast cancer by chemical ablation].
    Sun Q; Huang HY; Zhou YD; Mao F; Yang YQ; Xing Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Feb; 25(1):60-2. PubMed ID: 12905610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
    Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):495-508. PubMed ID: 7887641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A dose-comparative study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
    Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):477-94. PubMed ID: 7887640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist].
    Hisamatsu K; Iwamori S; Minami K; Tanabe K; Ota K; Akiyama H
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1327-30. PubMed ID: 9279354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The use of GnRH analogues in early and advanced breast carcinomas].
    Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
    Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer.
    Torrisi R; Colleoni M; Veronesi P; Rocca A; Peruzzotti G; Severi G; Medici M; Renne G; Intra M; Luini A; Nolè F; Viale G; Goldhirsch A
    Breast; 2007 Feb; 16(1):73-80. PubMed ID: 16908152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer.
    Dowsett M; Jacobs S; Aherne J; Smith IE
    Clin Ther; 1992; 14 Suppl A():97-103. PubMed ID: 1606596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of premenopausal breast cancer showing remarkable elevation of serum alkaline phosphatase level during treatment with LH-RH analog.
    Ito K; Komatsu A; Kanai T; Koyama H; Hama Y; Shingu K; Fujimori M; Amano J
    Breast J; 2005; 11(6):523-4. PubMed ID: 16297128
    [No Abstract]   [Full Text] [Related]  

  • 9. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):516-25. PubMed ID: 17405996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen.
    Berlière M; Galant C; Marques G; Piette P; Duck L; Fellah L; Donnez J; Machiels JP
    Eur J Cancer; 2004 Aug; 40(12):1855-61. PubMed ID: 15288287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
    Schmid P; Untch M; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Lehmann U; Maubach L; Meurer J; Wallwiener D; Possinger K
    J Clin Oncol; 2007 Jun; 25(18):2509-15. PubMed ID: 17577027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
    Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
    Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
    Ansari TN; Mahmood A; Hussain I; Samad A
    J Coll Physicians Surg Pak; 2005 Apr; 15(4):204-6. PubMed ID: 15857590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
    Ejlertsen B; Mouridsen HT; Jensen MB; Bengtsson NO; Bergh J; Cold S; Edlund P; Ewertz M; de Graaf PW; Kamby C; Nielsen DL
    J Clin Oncol; 2006 Nov; 24(31):4956-62. PubMed ID: 17075113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
    Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
    Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy for premenopausal patients with early breast cancer.
    Kurebayashi J
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):51-4. PubMed ID: 18197006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian ablation in the adjuvant treatment of premenopausal and perimenopausal breast cancer.
    Sainsbury R
    Br J Surg; 2003 May; 90(5):517-26. PubMed ID: 12734855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete estrogen blockade with buserelin and aminoglutethimide for advanced breast cancer: a phase I-II study with long-term hormonal correlations.
    Ferrari V; Zaniboni A; Simoncini E; Marpicati E; Montini E; Moretti R; Marini G
    Chemioterapia; 1988 Dec; 7(6):414-9. PubMed ID: 3146444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.